The National Agency for Food and Drug Administration and Control has warned healthcare providers, patients, and the public about the falsification and parallel importation of three batches of a NAFDAC-registered product: Dostinex 0.5mg Tablets.
In a public alert No. 07/2026 titled “Alert on Surveillance and mop up of Counterfeit Dostinex (0.5mg) tablets Found in Circulation,” the agency identified the affected batch numbers as GG3470, LG8659, and GG2440, with expiry dates June 2027, January 2026, and April 2026, respectively.
The products, manufactured by Pfizer Italia S.R.L, Ascoli Piceno, Italy, carry no NAFDAC Registration Number.
According to NAFDAC, “Pfizer Nigeria Ltd, the Marketing Authorisation Holder of the products, has confirmed the presence of falsified and parallel unregistered imported versions, even as it noted that although the legitimate product has been registered it is yet to be imported into Nigeria.”
“Dostinex 0.5 mg is a medication that reduces prolactin secretion, helping to alleviate symptoms caused by excess prolactin. The potency of products is highly dependent on complying with regulatory requirements. Falsified, unlicensed, and unregistered medicines present significant risks to public health because these products have not been evaluated by NAFDAC. Therefore, the quality, safety, and efficacy of these products cannot be guaranteed,” the agency stated.
NAFDAC directed all its zonal directors and state coordinators to carry out surveillance and mop up the unregistered products if found within the zones and states.
“Distributors, retailers, healthcare professionals, and caregivers are hereby advised to note the discrepancies stated above, exercise caution and vigilance within the supply chain to avoid the distribution, sale, and use of the unregistered products. All medical products must be obtained from authorised/licensed suppliers. The products’ authenticity and physical condition should be carefully checked,” the agency advised.
Healthcare professionals are advised to review stocks within hospitals, clinics, and pharmacy stores, and report any suspected falsified or compromised products to the nearest NAFDAC office, via the NAFDAC hotline at 0800-162-3322, or through email at sf.alert@nafdac.gov.ng.
Healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the E-reporting platforms available on the NAFDAC website.
